Cargando…
An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains
In this study, the cell free modified tryptone soya broth (pH 7.4 ± 0.2) of Bacillus subtilis URID 12.1 showed significant antimicrobial activity against multidrug-resistant strains of Staphylococcus aureus, S. epidermidis, Streptococcus pyogenes and Enterococcus faecalis. The partially purified ant...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678185/ https://www.ncbi.nlm.nih.gov/pubmed/26696963 http://dx.doi.org/10.3389/fmicb.2015.01335 |
_version_ | 1782405409798094848 |
---|---|
author | Chalasani, Ajay G. Dhanarajan, Gunaseelan Nema, Sushma Sen, Ramkrishna Roy, Utpal |
author_facet | Chalasani, Ajay G. Dhanarajan, Gunaseelan Nema, Sushma Sen, Ramkrishna Roy, Utpal |
author_sort | Chalasani, Ajay G. |
collection | PubMed |
description | In this study, the cell free modified tryptone soya broth (pH 7.4 ± 0.2) of Bacillus subtilis URID 12.1 showed significant antimicrobial activity against multidrug-resistant strains of Staphylococcus aureus, S. epidermidis, Streptococcus pyogenes and Enterococcus faecalis. The partially purified antimicrobial molecule was found to be resistant to extremes of pH and temperatures and also to higher concentrations of trypsin and proteinase K. The antimicrobial molecule was purified by a three-step method that included reversed-phase high performance liquid chromatography (RP-HPLC). The minimum inhibitory concentration (MIC) values were determined for 14 species of bacteria using a microbroth dilution technique. The HPLC-purified fraction showed the MICs ranging from 0.5 to 16 μg/ml for methicillin and vancomycin-resistant Staphylococcus aureus (MVRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) strains. The molecular mass of the antimicrobial compound was determined to be 842.37 Da. The same antimicrobial fraction showed negligible haemolytic activity against human red blood cells even at a concentration as high as 100 μg/ml. Because of its significant antimicrobial activity at low MIC values coupled with its non-haemolytic property, it may prove to be a novel antimicrobial lead molecule. |
format | Online Article Text |
id | pubmed-4678185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-46781852015-12-22 An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains Chalasani, Ajay G. Dhanarajan, Gunaseelan Nema, Sushma Sen, Ramkrishna Roy, Utpal Front Microbiol Microbiology In this study, the cell free modified tryptone soya broth (pH 7.4 ± 0.2) of Bacillus subtilis URID 12.1 showed significant antimicrobial activity against multidrug-resistant strains of Staphylococcus aureus, S. epidermidis, Streptococcus pyogenes and Enterococcus faecalis. The partially purified antimicrobial molecule was found to be resistant to extremes of pH and temperatures and also to higher concentrations of trypsin and proteinase K. The antimicrobial molecule was purified by a three-step method that included reversed-phase high performance liquid chromatography (RP-HPLC). The minimum inhibitory concentration (MIC) values were determined for 14 species of bacteria using a microbroth dilution technique. The HPLC-purified fraction showed the MICs ranging from 0.5 to 16 μg/ml for methicillin and vancomycin-resistant Staphylococcus aureus (MVRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) strains. The molecular mass of the antimicrobial compound was determined to be 842.37 Da. The same antimicrobial fraction showed negligible haemolytic activity against human red blood cells even at a concentration as high as 100 μg/ml. Because of its significant antimicrobial activity at low MIC values coupled with its non-haemolytic property, it may prove to be a novel antimicrobial lead molecule. Frontiers Media S.A. 2015-12-15 /pmc/articles/PMC4678185/ /pubmed/26696963 http://dx.doi.org/10.3389/fmicb.2015.01335 Text en Copyright © 2015 Chalasani, Dhanarajan, Nema, Sen and Roy. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Chalasani, Ajay G. Dhanarajan, Gunaseelan Nema, Sushma Sen, Ramkrishna Roy, Utpal An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains |
title | An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains |
title_full | An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains |
title_fullStr | An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains |
title_full_unstemmed | An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains |
title_short | An Antimicrobial Metabolite from Bacillus sp.: Significant Activity Against Pathogenic Bacteria Including Multidrug-Resistant Clinical Strains |
title_sort | antimicrobial metabolite from bacillus sp.: significant activity against pathogenic bacteria including multidrug-resistant clinical strains |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678185/ https://www.ncbi.nlm.nih.gov/pubmed/26696963 http://dx.doi.org/10.3389/fmicb.2015.01335 |
work_keys_str_mv | AT chalasaniajayg anantimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains AT dhanarajangunaseelan anantimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains AT nemasushma anantimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains AT senramkrishna anantimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains AT royutpal anantimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains AT chalasaniajayg antimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains AT dhanarajangunaseelan antimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains AT nemasushma antimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains AT senramkrishna antimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains AT royutpal antimicrobialmetabolitefrombacillusspsignificantactivityagainstpathogenicbacteriaincludingmultidrugresistantclinicalstrains |